Gary Gottlieb is in a prime spot to see how technology companies are shaking up health care.
Health and Human Services Secretary Alex Azar had a stern warning for the pharmaceutical industry on Friday, a day after the Trump administration proposed a plan to change the way Medicare pays for certain expensive drugs.
President Donald Trump said Medicare will start negotiating drug prices to bring costs in line for its Part B coverage with what other nations pay for the same drugs.
The booming U.S. economy appears to be reducing dependence on federal health insurance for the poor.
Tesla CEO Elon Musk briefly moved away from talking about cars during Wednesday’s earnings call to rave about his company’s new health clinics for employees.
Udi Manber, who ran engineering for Google’s core search products and previously held senior roles at Yahoo and Amazon, is joining health insurance giant Anthem as the head of artificial intelligence, according to people familiar with the matter.
Biotech giant Amgen is lowering the price of its cholesterol medicine Repatha by almost 60 percent, following a similar move from its competitor, after both drugs failed to meet sales expectations. The new price of the medicine will be $5,850 per year, Amgen said in a statement Wednesday. That’s down from an annual price of
The Food and Drug Administration has approved Xofluza, the first new antiviral flu treatment in nearly 20 years.
Tracy Pugh, an event planner based in Oakland, Calif., had a hard time breastfeeding her second child. So, when her third baby was just a few weeks old, she decided to invest about $1,000 into a “smart” breast pump from a Silicon Valley-backed start-up called Naya Health.
Don’t look now, but America’s first Trump-era midterm election could substantially expand Obamacare.
Leading e-cigarette manufacturer Juul spent half a million dollars on lobbying last quarter — up 167 percent from the previous quarter — as regulators weigh restrictions on the industry to stem a surge in teens using the devices.
Uncle Sam has a birthday gift for certain people who make it to 100: A tax bill.
When pharma giant Pfizer announced in January it planned to shut down early- and mid-stage neuroscience drug development, it was another blow to a field already in a defensive crouch.